The data behind the hype comes from the Phase 2b VESPER-3 trial, presented at the American Diabetes Association Scientific Sessions in June 2026. Across four dose regimens, berobenatide produced significantly greater weight loss than placebo at week 28, with the highest regimen — 4.8 mg monthly — delivering placebo-adjusted weight loss of up to 12.3%. Notably, weight loss had not plateaued when the trial ended, suggesting longer treatment could produce larger results.
Side effects looked like what GLP-1 patients already know: gastrointestinal events — nausea, and related stomach issues — that were mostly mild or moderate. Dr. John Buse, who presented the data, framed the goal plainly: "If approved, berobenatide has the potential to be not only effective, but practical and sustainable in real life."
For context, that 12.3% figure at 28 weeks sits below the headline numbers from weekly tirzepatide or investigational combinations like CagriSema — but those are different trials with different designs and durations, so direct comparisons are unreliable. The honest summary: berobenatide's weight loss looks solidly in the effective range, and its selling point is convenience, not record-breaking efficacy.